What the FDA labels say about taking them together
Meloxicam and piroxicam
Piroxicam's FDA label of August 19, 2026 names meloxicam in its drug interactions section; meloxicam's label does not name piroxicam itself but warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)). The piroxicam label: “Concomitant use of piroxicam and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity.”
Check it at the source: the meloxicam FDA label on DailyMed (effective January 29, 2026, PD-Rx Pharmaceuticals, Inc.); the piroxicam FDA label on DailyMed (effective August 19, 2026, Teva Pharmaceuticals USA, Inc.).
What does the meloxicam label say about piroxicam?
Meloxicam's label does not name piroxicam itself; it warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)):
Meloxicam label, boxed warningGastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
Meloxicam label, boxed warningThis risk may occur early in treatment and may increase with duration of use (5.1) Meloxicam tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (4, 5.1) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
Source: FDA drug label (MELOXICAM), PD-Rx Pharmaceuticals, Inc., effective January 29, 2026 (SPL set 19c13159-71f1-2427-e063-6394a90ad44e), via openFDA; the full label on DailyMed
What does the piroxicam label say about meloxicam?
Piroxicam label, drug interactionsPemetrexed Clinical Impact: Concomitant use of piroxicam and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (…). … absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.
Source: FDA drug label (Piroxicam), Teva Pharmaceuticals USA, Inc., effective August 19, 2026 (SPL set f1123fe1-b79c-430b-8548-08cd6e518482), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Meloxicam | Piroxicam | |
|---|---|---|
| Labeled for | Osteoarthritis, Rheumatoid arthritis, Pain | Osteoarthritis, Rheumatoid arthritis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.0166 per tablet 7.5 mg tablet | $0.215 per capsule 20 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once